An experimental drug designed to slow cognitive decline in those with Alzheimer’s disease ran into a buzz saw of skepticism Friday as government advisers said there was not enough evidence to show that the drug was effective. The reaction raised questions about whether the Food and Drug Administration would approve the drug, which would be the first new Alzheimer’s treatment in almost two decades.